Compare VERA & BSTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VERA | BSTZ |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2021 | N/A |
| Metric | VERA | BSTZ |
|---|---|---|
| Price | $30.10 | $25.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $71.93 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 179.5K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.31% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $695.74 | N/A |
| P/E Ratio | ★ N/A | $35.70 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.38 | $20.69 |
| 52 Week High | $56.05 | $31.89 |
| Indicator | VERA | BSTZ |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 37.09 |
| Support Level | $26.92 | $24.75 |
| Resistance Level | $32.94 | $29.36 |
| Average True Range (ATR) | 1.86 | 0.91 |
| MACD | 0.18 | -0.18 |
| Stochastic Oscillator | 47.93 | 34.25 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
BlackRock Science and Technology Trust II is a diversified, closed-end management investment company. Its investment objectives are to provide total return and income mainly through long-term capital appreciation. The Trust invests a majority of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement, and use of science and/or technology. Its investment portfolio comprises securities of companies from various industries, such as semiconductors and semiconductor equipment, software, communications equipment, IT services, and entertainment, etc.